New scan may help match breast cancer patients to the right drug
NCT ID NCT07471776
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether a new type of PET scan (TROP2-PET) can predict how well certain targeted drugs work in people with advanced HER2-negative breast cancer. The drugs, called antibody-drug conjugates, deliver chemotherapy directly to cancer cells. The study will enroll 45 participants and compare the TROP2-PET scan with a standard FDG-PET scan to see which better predicts treatment response. If successful, this approach could help doctors choose the most effective treatment for each patient.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Sacituzumab Govitecan, Datopotamab deruxtecan, Sacituzumab tirumotecan (targeted cancer drugs)
- What this could lead to
- If successful, this imaging method could help doctors predict which patients will benefit from TROP2-targeted drugs, avoiding ineffective treatments.
- What could go wrong
- This is a small, early-phase study (45 participants) focused on imaging accuracy, not treatment outcomes. The prediction model may not be reliable enough for routine use.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
About 45 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2026
- Expected to finish
-
Mar 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients diagnosed with advanced/metastatic HER2-negative breast cancer with confirmed metastatic disease, regardless of being de novo diagnosed or progressed from a non-metastatic stage. * Patients who are planned to receive anti-TROP2 antibody-drug conjugate (ADC) therapy (e.g., sacituzumab govitecan or datopotamab deruxtecan) as part of routine clinical care. * Patients who will undergo protocol-defined \^68Ga-TROP2 PET/CT and \^18F-FDG PET/CT during the study (baseline imaging, with repeat imaging per protocol if applicable). * Adult patients (≥18 years) who are able to provide informed consent and comply with study procedures. Exclusion Criteria: * Patients with incomplete medical records or inability to complete the required imaging assessments. * Patients with prior exposure to an anti-TROP2 ADC. * Patients with known contraindications to PET/CT or known allergy to \^18F-FDG or the \^68Ga-TROP2 tracer (or their components). * Patients who are pregnant or breastfeeding. * Patients diagnosed with secondary primary tumors (other active malignancies), as determined by the investigator.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Metastatic breast cancer ( HER2 negative) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200032, China
-
Fudan University Shanghai Cancer Center
NOT_YET_RECRUITINGShanghai, 200032, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.